Zydus Lifesciences has received approval from WHO International Non-proprietary Names (INN) for “Usnoflast” as the recommended name for ZYIL1. The INN system aims to provide healthcare professionals with a unique and universal designated name for each pharma substance.
Jubilant Pharmova's wholly owned subsidiary Jubilant Pharma, today announced that its subsidiary Jubilant Generics (JGL) received a communication from the USFDA through which the regulatory agency intimated that pursuant to its January 25 to February 2, 2024 audit of JGL's Solid dosage manufacturing facility at Roorkee
FDA slams Jubilant Generics, Canada`s Contract Pharmaceuticals with Form 483s
FDA Issues form 483 to Jubilant Generics
Jubilant Generics` Roorkee site completes USFDA audit
Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Pharma Limited, has announced that its subsidiary Jubilant Generics Limited (JGL) has received a communication from the USFDA through which the latter intimated that pursuant to its July-Aug 2022 audit of JGL’s Solid Dosage Manufacturing facility at Roorkee it has determined inspection classification of the facility as “official action indicated”.
FDA Issues Form 483 to Jubilant Generics Ltd.
Indian site for Jubilant Generics lands Form 483 for QC issues
Jubilant Generics (Roorkee) is on Health Canada Inspection List
FDA issues form 483 to Jubilant Generics